Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents https://www.biorxiv.org/content/10.1101/2023.07.02.547392v1?med=mas
Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents https://www.biorxiv.org/content/10.1101/2023.07.02.547392v1?med=mas